title: Pathological findings in Gaucher disease type 2 patients following enzyme therapy.
abstract: The pathological outcomes following intravenous acid beta-glucosidase (alglucerase) infusions were compared in two siblings with Gaucher disease type 2, the acute neuronopathic variant. In case 1 enzyme infusions (four doses at 7 months) had no effect when severe progressive visceral and neuronopathic disease were present. Death from progressive disease occurred at 9 months. Case 2 was prenatally diagnosed. Enzyme infusions were initiated presymptomatically at 4 days of age and continued until death at 15.2 months. Development progressed satisfactorily, albeit at a slower than normal rate until age 10 months when progressive brain stem involvement became evident. Death occurred after slowly progressive brain stem dysfunction, but gross motor and cognitive skills were nearly normal. Postmortem light and electron microscope (EM) studies in both cases showed typical central nervous system (CNS) findings and massive infiltration of the lungs and lymph nodes by Gaucher cells. The liver, spleen, and bone marrow, except that in the temporal bone, in case 2 were normal. These studies show that enzyme therapy may slow but does not prevent the development of lethal CNS disease in Gaucher disease type 2, even when initiated presymptomatically. These findings also indicate the nonuniformity of tissue responses to enzyme therapy implying the existence of therapeutically inaccessible compartments that, in less severe variants, may create unexpected long-term disease complications.
authors.affiliation: Children's Hospital Research Foundation, Division of Pathology, Cincinnati, OH 45229-3039, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Bove
authors.forename: C
authors.initials: C
authors.lastname: Daugherty
authors.forename: G A
authors.initials: GA
authors.lastname: Grabowski
mesh_terms: D017809:Fatal Outcome; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D005962:Glucosylceramidase / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D011296:Prenatal Diagnosis
chemical_list: C070292:alglucerase; D005962:Glucosylceramidase